Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TTN/TP53 mutation might act as the predictor for chemotherapy response in lung adenocarcinoma and lung squamous carcinoma patients

1 Mar 2021

Abstract excerpt

Background: Chemotherapy is the preferred treatment in many types of cancer including lung cancer. However, most of patients resist chemotherapy resulting in disease progressive and recurrence. Titin (TTN) mutation is proved as a beneficial role in lung squamous carcinoma (LUSC), but the predictive role on chemotherapy resistance of lung cancer is still limited and discussable. Methods: Clinical information and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Lung Cancer Diagnosis and Treatment
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35116455
DOI: 10.21037/tcr-20-2568

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TTN/TP53 mutation might act as the predictor for chemotherapy response in lung adenocarcinoma and lung squamous carcinoma patientsPMID 35116455Read ↗

Co-mutation of TP53 and TTN is Correlated with the Efficacy of Immunotherapy in Lung Squamous Cell Carcinoma.Semantic proximity Read ↗

Differences in Genetics and Microenvironment of Lung Adenocarcinoma Patients with or without TP53 MutationSemantic proximity Read ↗

Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based ChemotherapySemantic proximity Read ↗

Genomic landscape and prognosis of patients with TP53-mutated non-small cell lung cancerSemantic proximity Read ↗

Lung cancer pathogenesis and poor response to therapy were dependent on driver oncogenic mutations.Semantic proximity Read ↗

Analysis of gene mutation spectrum and prevention and treatment of lung cancer patients in Qujing, Yunnan Province, ChinaSemantic proximity Read ↗

TP53 Co-Mutations in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer TherapySemantic proximity Read ↗

Prognostic value of tumor mutation burden in non-small cell lung cancer: A Meta-Analysis and system reviewSemantic proximity Read ↗

Integrated Multi-Omics and Transcriptomic Validation Analysis of TP53, ATM, BRCA1, EGFR, and KRAS Reveals Prognostic Significance in Lung CancerSemantic proximity Read ↗

Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation.Semantic proximity Read ↗

Titin Mutation Is Associated With Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Squamous Cell CarcinomaSemantic proximity Read ↗

Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.